Multiagent Combo Bests Immunotherapy Alone against Colorectal Cancer
Abstract
Compared with atezolizumab monotherapy, a combination of chemotherapy, atezolizumab, and bevacizumab led to dramatically improved progression-free survival in patients with mismatch repair-deficient /microsatellite instability-high metastatic colorectal cancer. Because these patients often experience disease progression on immunotherapy, the results suggest that the combination approach could improve how they fare.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Colorectal Cancer Treatments and Studies
Genetic factors in colorectal cancer
Publication details
- Journal / source
- Cancer Discovery
- Volume
- 16
- Issue
- 3
- Pages
- OF1–OF1
- Publication date
- 12 January 2026
- Language
- EN